Claritev (CTEV) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $230.5 million, down 5.1% year-over-year, with Adjusted EBITDA of $141.6 million and a margin of 61.5%.

• Net loss for Q3 2024 was $391.5 million, primarily due to a $361.6 million impairment of goodwill and indefinite-lived intangibles.

• Identified potential medical cost savings reached $6.4 billion, up 10% year-over-year, with 165 sales opportunities closed and four new clients added.

• Vision 2030 transformation and efficiency programs are underway, with leadership expanded by a new CFO and Chief Growth Officer.

• A 1-for-40 reverse stock split was completed in September 2024 to regain NYSE compliance.

Financial highlights

• Adjusted EBITDA was $141.6 million, down 7% year-over-year and 3.4% sequentially; margin was 61.5%, down from 62.7% in Q3 2023.

• Net cash from operating activities was $72.8 million; free cash flow was $41.1 million; unrestricted cash at quarter-end was $86.6 million.

• Net loss for Q3 2024 was $391.5 million, mainly due to a $361.6 million impairment charge.

• Processed $44.7 billion in claim charges in Q3 2024.

• Shareholders' equity declined to $207.6 million from $1.71 billion at year-end 2023, mainly due to impairment charges.

Outlook and guidance

• FY 2024 revenue guidance narrowed to $930–$940 million, down from $935–$955 million.

• Adjusted EBITDA guidance for FY 2024 narrowed to $580–$590 million.

• Operating cash flow expected at $135–$145 million; Q4 2024 expected to be similar to Q3 2024.

• Business stabilization expected through the first half of 2025, with updated 2025 outlook to be provided in February.